Document is current
Any future updates will be listed below
-
Authors
Eriksson, Jan W. https://orcid.org/0000-0002-2639-9481
Pereira, Maria J. https://orcid.org/0000-0001-5498-3899
Kagios, Christakis https://orcid.org/0000-0003-1270-2221
Kvernby, Sofia https://orcid.org/0000-0001-9093-404X
Lundström, Elin https://orcid.org/0000-0003-2955-4958
Fanni, Giovanni https://orcid.org/0000-0002-7920-8909
Lundqvist, Martin H. https://orcid.org/0000-0001-9348-4603
Carlsson, Björn C. L. https://orcid.org/0000-0002-3023-9878
Sundbom, Magnus https://orcid.org/0000-0002-6243-2859
Tarai, Sambit https://orcid.org/0000-0002-5550-3575
Lubberink, Mark https://orcid.org/0000-0001-8324-7399
Kullberg, Joel https://orcid.org/0000-0001-8205-7569
Risérus, Ulf https://orcid.org/0000-0002-8620-4586
Ahlström, Håkan https://orcid.org/0000-0002-8701-969X
-
Funding
Funding for this research was provided by:
HORIZON EUROPE Marie Sklodowska-Curie Actions (H2020-MSCA-ITN-721236)
Uppsala University ALF grants
Diabetesförbundet
Agnes och Mac Rudbergs Stiftelse
HORIZON EUROPE European Innovation Council (101080329)
Stiftelsen Familjen Ernfors Fond
AstraZeneca Mölndal
Excellence of Diabetes Research in Sweden
Novo Nordisk Fonden (NNF20OC0063864)
Novo Nordisk Fonden (NNF23OC0084483)
P. O. Zetterlings stiftelse
Uppsala University
- License Information
-
More Information
Article History
Received: 26 October 2023
Accepted: 1 March 2024
First Online: 24 April 2024
Acknowledgements
: We thank all staff involved in the study from all collaborating departments of Uppsala University and Uppsala University Hospital. We are also grateful to the patients for participating in the uncomfortable and time-consuming investigations.
: The datasets generated during and/or analysed during the current study are available from the corresponding authors upon reasonable request.
: Open access funding provided by Uppsala University. This work was supported by research grants from AstraZeneca R&D, the Swedish Diabetes Foundation, the European Union’s Horizon Europe Research project PAS GRAS under grant agreement no. 101080329, the European Commission via the Marie Sklodowska Curie Innovative Training Network TREATMENT (H2020-MSCA-ITN-721236), EXODIAB, the Family Ernfors Foundation, the P.O. Zetterling Foundation, Novo Nordisk Foundation (NNF20OC0063864, NNF23OC0084483), the Agnes and Mac Rudberg Foundation and the Uppsala University Hospital ALF grants.
: BCLC is an employee at Astra Zeneca R&D. The other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: JWE, HA and UR conceived and designed the research. The investigation phase involved MJP, CK, SK, EL, BCLC, MS, ST, MHL, JK, ML and UR. JWE, MJP, CK, GF and SK contributed to formal analyses and interpretation of the data. JWE, HA and MJP received funding. JWE, MJP, CK, SK, EL, GF, ML, ST, JK and UR drafted the paper. All authors critically revised and approved the final version to be submitted. JWE and HA are the guarantors of this work.
